108 related articles for article (PubMed ID: 15860893)
1. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas.
De Preter K; Speleman F; Combaret V; Lunec J; Board J; Pearson A; De Paepe A; Van Roy N; Laureys G; Vandesompele J
J Clin Oncol; 2005 May; 23(13):3167-8; author reply 3168-70. PubMed ID: 15860893
[No Abstract] [Full Text] [Related]
2. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
3. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
4. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
5. Expression of two dead box genes (DDX1 and DDX6) is independent of that of MYCN in human neuroblastoma cell lines.
Akiyama K; Akao Y; Yokoyama M; Nakagawa Y; Noguchi T; Yagi K; Nishi Y
Biochem Mol Biol Int; 1999 Apr; 47(4):563-8. PubMed ID: 10319407
[TBL] [Abstract][Full Text] [Related]
6. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus.
Noguchi T; Akiyama K; Yokoyama M; Kanda N; Matsunaga T; Nishi Y
Genes Chromosomes Cancer; 1996 Feb; 15(2):129-33. PubMed ID: 8834177
[TBL] [Abstract][Full Text] [Related]
7. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
Amler LC; Schürmann J; Schwab M
Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
[TBL] [Abstract][Full Text] [Related]
8. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
George RE; Kenyon RM; McGuckin AG; Malcolm AJ; Pearson AD; Lunec J
Oncogene; 1996 Apr; 12(7):1583-7. PubMed ID: 8622876
[TBL] [Abstract][Full Text] [Related]
9. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
10. Physical mapping of the DDX1 gene to 340 kb 5' of MYCN.
Kuroda H; White PS; Sulman EP; Manohar CF; Reiter JL; Cohn SL; Brodeur GM
Oncogene; 1996 Oct; 13(7):1561-5. PubMed ID: 8875996
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
12. Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?
Scott D; Elsden J; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):81-6. PubMed ID: 12880964
[TBL] [Abstract][Full Text] [Related]
13. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay.
De Preter K; Speleman F; Combaret V; Lunec J; Laureys G; Eussen BH; Francotte N; Board J; Pearson AD; De Paepe A; Van Roy N; Vandesompele J
Mod Pathol; 2002 Feb; 15(2):159-66. PubMed ID: 11850545
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
15. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
[No Abstract] [Full Text] [Related]
16. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
[TBL] [Abstract][Full Text] [Related]
17. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
18. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
19. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
20. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
